AFATINIB相关论文
目的:多形性胶质母细胞瘤（multiforme glioblastomas,GBMs）是一种原发于脑组织,最具侵袭性和致命性的恶性肿瘤之一,目前缺乏有效的治......
The Second Generation of TKI Afatinib Controls Inflammation by Regulating NLRP3 Inflammasome Activat
Objective Chronic inflammation might lead to many malignancies,and inadequate resolution could play a crucial role in tu......
Aims: Afatinib is a potent,irreversible and double tyrosine kinases inhibitor of EGFR and HER2,so we target is to synthe......
ABCB1-mediated multidrug resistance (MDR) remains a major obstacle to successful chemotherapy in ovarian cancer. Herein,......
Phase Ⅲ trial of afatinib vs erlotinib in patients (pts) with squamous cell carcinoma (SCC) of the l
Objective: Treatment options for pts with advanced SCC of the lung progressing after platinum-based chemotherapy are lim......
Afatinib enhances the efficacy of conventional chemotherapeutic agents by eradicating cancer stem-li
Background Cancer stem cells (CSC) have garnered significant attention as a therapeutic focus, based on evidence that th......
Afatinib enhances the efficacy of conventional chemotherapeutic agents by eradicating cancer stem-li
Cancer stem-like cells (CSC) have garnered significant attention as a therapeutic focus, based on evidence they may repr......
Synergic effect of HangAmDan-B1 (HAD-B1,三七虫草锭) combined with Afatinib on EGFR-L858R/T790M double mut
Aim: The purpose of this study is to evaluate the synergic effect of HAD-B 1 (Panax Notoginseng Radix, Cordyceps militar......
Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F compound mutation benef
BACKGROUND Epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKIs)have been adopted as the standard of ca......
Development of a competitive enzyme-linked immunosorbent assay for therapeutic drug monitoring of af
Afatinib is an oral tyrosine kinase inhibitor (TKI) approved for treating advanced non-small cell lung cancer. It is nec......
美国FDA于2013年7月12日批准了Boe-hringer Ingelheim公司开发的酪氨酸激酶抑制剂类抗癌药afatinib(Gilotrif)用于一线治疗携有表......
美国FDA于2013年7月12日批准了Boe-hringer Ingelheim公司开发的酪氨酸激酶抑制剂类抗癌药afatinib(Gilotrif)用于一线治疗携有表......
表皮生长因子受体(epidermal growth factor receptor,EGFR)的发现和EGFR酪氨酸激酶抑制剂(EGFR tyrosine kinase inhibitors,EGFR......
第一部分 Afatinib作为第二代表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)，已有证据显示其对EGFR敏感型突变非小细胞肺癌患者疗......
Objective:Several predictors of survival have been identified in EGFR-positive non-small cell lung cancer (NSCLC) patien......
Clinical efficacy of bevacizumab combined with afatinib in the treatment of non-small cell lung canc
为探究吕家坨井田地质构造格局,根据钻孔勘探资料,采用分形理论和趋势面分析方法,研究了井田7......
Efficacy of afatinib in a patient with rare EGFR(G724S/R776H)mutations and amplification in lung ade
BACKGROUND The most common EGFR mutations are in-frame deletions in exon 19 and point mutations in exon 21.Cases with cl......
恶性肿瘤严重威胁人们的生命健康,尤其是肺癌。随着对肺癌分子生物学的深入研究以及相关靶向药物的开发,靶向治疗已经改变了晚期肺......
目的探讨阿法替尼一线治疗EGFR突变晚期非小细胞肺癌(non-small-cell lung cancer,NSCLC)剂量的选择。方法回顾性分析宝鸡市人民医......
目的探讨固摄扶正抗癌汤联合阿法替尼、培美曲塞治疗非小细胞肺癌的临床效果。方法收集2017年1月-2019年2月来我院治疗的晚期非小......
目的观察阿法替尼治疗人表皮生长因子受体(EGFR)突变阳性晚期非小细胞肺癌(NSCLC)患者的临床疗效和不良反应。方法91例晚期NSCLC患......
目的探讨阿法替尼增强耐药性卵巢癌细胞对多柔比星化疗敏感性的机制。方法选取人卵巢癌耐药细胞株A2780T,采用噻唑蓝(MTT)法检测不......
目的探究阿法替尼和顺铂分别联合培美曲塞治疗晚期EFGR突变型非小细胞肺癌晚期(non-small-cell carcinoma,NSCLC)的临床疗效差异,......
目的:建立以高效液相色谱法测定阿法替尼片中主药和有关物质含量的方法,以控制该制剂的质量。方法:色谱柱为Kromasil C18(250 mm×......
对阿法替尼合成工艺进行研究。以4-氟-2-氨基苯甲酸为起始原料，经环合、硝化、氯化、取代反应得到中间体6；中间体6与（S）-3-羟基四氢呋......
Objective: Several predictors of survival have been identified in EGFR-positive non-small cell lung cancer(NSCLC) patien......
下咽癌发病率较低,恶性程度高,预后差,易发生第二原发食管癌。对于下咽-食管多原发癌,目前尚无统一治疗方案。本文主要报道1例下咽......
Development of a competitive enzyme-linked immunosorbent assay for therapeutic drug monitoring of af
Afatinib is an oral tyrosine kinase inhibitor (TKI) approved for treating advanced non-small cell lung cancer. It is nec......
背景与目的阿法替尼是一种新型的低分子量人类表皮生长因子受体（humanepidermalgrowthfactorreceptor,HER）家族抑制剂，它属于第二代表......
A simple, controlled, robust and scalable three-stage manufacturing process of Afatinib Dimaleate was assessed and optim......
背景与目的:众周所知,肺癌是中国乃至世界的头号癌症杀手,且发病率持续增加,虽然根据肺癌的病理特征分为非小细胞肺癌和小细胞肺癌......
目的:本研究旨在探讨EGFR-TKIs在食管鳞癌细胞系中的抗肿瘤活性及分子机制,为食管鳞癌的综合治疗提供新的思路。方法:本研究采用CC......
